193 related articles for article (PubMed ID: 15655345)
1. How cancer could be cured by 2015.
Blagosklonny MV
Cell Cycle; 2005 Feb; 4(2):269-78. PubMed ID: 15655345
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Blagosklonny MV
Cancer Biol Ther; 2004 May; 3(5):436-40. PubMed ID: 15197345
[TBL] [Abstract][Full Text] [Related]
3. Highlights in Resistance Mechanism Pathways for Combination Therapy.
Delou JMA; Souza ASO; Souza LCM; Borges HL
Cells; 2019 Aug; 8(9):. PubMed ID: 31480389
[TBL] [Abstract][Full Text] [Related]
4. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
5. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
7. Selective induction of apoptosis: promising therapy in pancreatic cancer.
Liu Z; Li D; Zheng X; Wang E; Wang J
Curr Pharm Des; 2013; 19(12):2259-68. PubMed ID: 23082976
[TBL] [Abstract][Full Text] [Related]
8. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.
Banudevi S; Swaminathan S; Maheswari KU
Nutr Cancer; 2015; 67(7):1021-48. PubMed ID: 26359767
[TBL] [Abstract][Full Text] [Related]
10. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
11. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
12. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Milas L; Mason KA; Crane CH; Liao Z; Masferrer J
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):15-24. PubMed ID: 12800601
[TBL] [Abstract][Full Text] [Related]
13. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
16. Combinational strategies of metformin and chemotherapy in cancers.
Zhang HH; Guo XL
Cancer Chemother Pharmacol; 2016 Jul; 78(1):13-26. PubMed ID: 27118574
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer with kinase inhibitors.
Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
[TBL] [Abstract][Full Text] [Related]
18. Cancer chemoprevention by polyphenols and their potential application as nanomedicine.
Tabrez S; Priyadarshini M; Urooj M; Shakil S; Ashraf GM; Khan MS; Kamal MA; Alam Q; Jabir NR; Abuzenadah AM; Chaudhary AG; Damanhouri GA
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2013; 31(1):67-98. PubMed ID: 23534395
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
20. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
